According to the 2019 NCCN guidelines for NSCLC, what is the role of cell-free/circulating tumor DNA testing (liquid biopsy)?

A. Liquid biopsy is still experimental and should not be used.
B. Liquid biopsy should be used to confirm molecular test results on tissue samples.
C. Liquid biopsy and tumor tissue molecular testing should be performed concurrently.
D. Liquid biopsy may be used if a patient is medically unfit for invasive tissue sampling.

Liquid biopsy in NSCLC according to 2019 NCCN guidelines involves cell-free/circulating tumor DNA testing to detect mutations and aid in treatment decisions.

Explanation:

Liquid biopsy plays a crucial role in cancer diagnosis and treatment, especially in NSCLC according to the 2019 NCCN guidelines. It can provide valuable information through cell-free/circulating tumor DNA testing by detecting specific mutations in the blood, which can aid in treatment decisions.

The use of liquid biopsy alongside traditional tumor tissue molecular testing allows for a more comprehensive understanding of the cancer's genetic makeup. Additionally, liquid biopsy can be particularly beneficial when a patient is not suitable for invasive tissue sampling, enabling a less invasive yet effective method of monitoring cancer progression.

Learn more about The role of liquid biopsy in cancer diagnosis and treatment here:

https://brainly.com/question/7973252